Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.

Molecular cancer - 19 Feb 2018

Rocca Stefania, Carrà Giovanna, Poggio Pietro, Morotti Alessandro, Brancaccio Mara

Abstract excerpt

Atypical Chronic Myeloid Leukemia (aCML) is a myeloproliferative neoplasm characterized by neutrophilic leukocytosis and dysgranulopoiesis. From a genetic point of view, aCML shows a heterogeneous mutational landscape with mutations affecting signal transduction proteins but also broad genetic modifiers and chromatin remodelers, making difficult to understand the molecular mechanisms causing the onset of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinases
Share to Mitogen-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Pyrazoles

Share to Pyridones

Share to Pyrimidines

Share to Pyrimidinones

Share to rho-Associated Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29455651
DOI: 10.1186/s12943-018-0774-4
PMCID: PMC5817721

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia.PMID 29455651Read ↗

Atypical Chronic Myeloid Leukemia: Where Are We Now?Semantic proximity Read ↗

Atypical CML: diagnosis and treatment.Semantic proximity Read ↗

Current and evolving understanding of atypical chronic myeloid leukemia.Semantic proximity Read ↗

Atypical chronic myeloid leukemia: a rare entity with management challenges.Semantic proximity Read ↗

Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.Semantic proximity Read ↗

Molecular targeted therapy in acute myeloid leukemia.Semantic proximity Read ↗

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.Semantic proximity Read ↗

What's different about atypical CML and chronic neutrophilic leukemia?Semantic proximity Read ↗

Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.Semantic proximity Read ↗

Receptor tyrosine kinase alterations in AML - biology and therapy.Semantic proximity Read ↗

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Semantic proximity Read ↗

RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.